Tag Archives: Pfizer

Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

The J.P. Morgan Healthcare Conference may be over, but that doesn’t mean the dealmaking is. Often, deals that took shape at the meeting materialize later in the year, and some recent buzz puts Pfizer and Biogen at the center of potential takeovers. Pfizer is reportedly eyeing a buyout of cardiovascular player Amarin, whose fish-oil-derived lipid drug… Read More »

China's online healthcare platform jianke.com enters into strategic collaboration with Pfizer

Jianke.com, China’s online healthcare platform, yesterday announced during the Jianke Doctor Rebrand & 2018 Jianke Partners’ Conference in Shanghai that they will be entering into a strategic partnership with US-based global pharmaceutical leader Pfizer. Both companies will leverage their leadership in their respective fields and successful practices to implement a patient-focused strategy in terms of… Read More »

Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount

After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching anemia treatment Retacrit at a significant discount to Amgen’s Epogen and Johnson & Johnson’s Procrit. Pfizer started shipping Retacrit to wholesalers on Monday at… Read More »